Advertisement

Targeted Oncology

, Volume 14, Issue 6, pp 639–645 | Cite as

First-Line Systemic Therapy for Metastatic Clear-Cell Renal Cell Carcinoma: Critical Appraisal of Emerging Options

  • Vivian Loo
  • Meghan Salgia
  • Paulo Bergerot
  • Errol J. Philip
  • Sumanta K. PalEmail author
Review Article

Abstract

Until recently, a dichotomy existed in the front-line approach of metastatic clear-cell renal cell carcinoma (mRCC). Specifically, patients received either targeted therapy or immunotherapy. Targeted therapy entailed use of agents blocking signaling through the vascular endothelial growth factor (VEGF) receptor, such as cabozantinib, sunitinib, or pazopanib. Immunotherapy entailed dual therapy with nivolumab and ipilimumab, both checkpoint inhibitors for intermediate/poor International Metastatic RCC Database Consortium (IMDC)-risk disease patients. Within the past year, two datasets have emerged that led to recent approvals of combined therapy with VEGF and checkpoint inhibitors. These regimens (axitinib with either avelumab or pembolizumab) are among several that have been or will be evaluated for patients with newly diagnosed mRCC. We aim to facilitate treatment decisions through this comprehensive and contextualized overview of recent datasets in this therapeutic space.

Notes

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this article.

Conflict of interest

Vivian Loo, PharmD, Meghan Salgia, Paulo Bergerot, MD, and Errol J. Philip, PhD declare that they have no conflicts of interest that might be relevant to the contents of this article. Sumanta K. Pal, MD: Honoraria: Novartis, Medivation, Astellas Pharma; Consulting or Advisory Role: Pfizer, Novartis, Aveo, Myriad; Pharmaceuticals, Genentech, Exelixis, Bristol-Myers Squibb, Astellas Pharma; Research Funding: Medivation.

References

  1. 1.
    Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376:354–66.CrossRefGoogle Scholar
  2. 2.
    Salgia NJ, Dara Y, Bergerot P, et al. The changing landscape of management of metastatic renal cell carcinoma: current treatment options and future directions. Curr Treat Options Oncol. 2019;20:41.CrossRefGoogle Scholar
  3. 3.
    Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113:293–301.CrossRefGoogle Scholar
  4. 4.
    Rosenblatt J, McDermott DF. Immunotherapy for renal cell carcinoma. Hematol Oncol Clin N Am. 2011;25:793–812.CrossRefGoogle Scholar
  5. 5.
    Singh P, Agarwal N, Pal SK. Sequencing systemic therapies for metastatic kidney cancer. Curr Treat Options Oncol. 2015;16:316.CrossRefGoogle Scholar
  6. 6.
    Lalani AA, Li H, Heng DYC, et al. First-line sunitinib or pazopanib in metastatic renal cell carcinoma: the Canadian experience. Can Urol Assoc J. 2017;11:112–7.CrossRefGoogle Scholar
  7. 7.
    Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13.CrossRefGoogle Scholar
  8. 8.
    Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378:1277–90.CrossRefGoogle Scholar
  9. 9.
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.CrossRefGoogle Scholar
  10. 10.
    Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35:591–7.CrossRefGoogle Scholar
  11. 11.
    Yip SM, Wells C, Moreira R, et al. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer. 2018;124:3677–83.CrossRefGoogle Scholar
  12. 12.
    Amin A, Plimack ER, Ernstoff MS, et al. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018;6:109.CrossRefGoogle Scholar
  13. 13.
    Bergerot P, Burns K, Prajapati D, et al. Advances in the treatment of metastatic renal cell carcinoma. Cancer Treat Res. 2018;175:127–37.CrossRefGoogle Scholar
  14. 14.
    Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma. Nat Commun. 2016;7:12624.CrossRefGoogle Scholar
  15. 15.
    Choueiri TK, Larkin J, Oya M, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018;19:451–60.CrossRefGoogle Scholar
  16. 16.
    Atkins MB, Plimack ER, Puzanov I, et al. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol. 2018.Google Scholar
  17. 17.
    Escudier B, Barthelemy P, Ravaud A, et al. Tivozanib combined with nivolumab: phase Ib/II study in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2018;36:618.CrossRefGoogle Scholar
  18. 18.
    Choueiri TK, Apolo AB, Powles T, et al. A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER). J Clin Oncol. 2018;36:TPS4598.CrossRefGoogle Scholar
  19. 19.
    George S, Rini BI, Hammers HJ. Emerging role of combination immunotherapy in the first-line treatment of advanced renal cell carcinoma: a review. JAMA Oncol. 2018.Google Scholar
  20. 20.
    Flippot R, Escudier B, Albiges L. Immune checkpoint inhibitors: toward new paradigms in renal cell carcinoma. Drugs. 2018;78:1443–57.CrossRefGoogle Scholar
  21. 21.
    Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116–27.CrossRefGoogle Scholar
  22. 22.
    Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103–15.CrossRefGoogle Scholar
  23. 23.
    Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019.Google Scholar
  24. 24.
    Tannir NM, Frontera OA, Hammers HJ, et al. Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N + I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol. 2019;37:547.CrossRefGoogle Scholar
  25. 25.
    Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1814–23.CrossRefGoogle Scholar
  26. 26.
    Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:917–27.CrossRefGoogle Scholar
  27. 27.
    Mejean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379:417–27.CrossRefGoogle Scholar
  28. 28.
    Vaishampayan U. SWOG PROBE in Pal SK, Editors SWOG Spring meeting. 2019.Google Scholar
  29. 29.
    Motzer RJ, Powles T, Atkins MB, et al. IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2018;36:578.CrossRefGoogle Scholar
  30. 30.
    Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794–9.CrossRefGoogle Scholar
  31. 31.
    Diab A, Tannir NM, Bernatchez C, et al. A phase 1/2 study of a novel IL-2 cytokine, NKTR-214, and nivolumab in patients with select locally advanced or metastatic solid tumors. J Clin Oncol. 2017;35:e14040.CrossRefGoogle Scholar
  32. 32.
    ClinicalTrials.gov: A study of NKTR-214 in combination with nivolumab compared with the investigator’s choice of a tyrosine kinase inhibitor (TKI) therapy (Either Sunitinib or Cabozantinib Monotherapy) for advanced metastatic renal cell carcinoma (RCC)—NCT03729245, 2019.Google Scholar
  33. 33.
    Hoerner CR, Chen VJ, Fan AC. The ‘Achilles Heel’ of metabolism in renal cell carcinoma: glutaminase inhibition as a rational treatment strategy. Kidney Cancer. 2019;3:15–29.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Vivian Loo
    • 1
  • Meghan Salgia
    • 2
  • Paulo Bergerot
    • 2
  • Errol J. Philip
    • 3
  • Sumanta K. Pal
    • 2
    Email author
  1. 1.Department of Protocol Content AdministrationCity of Hope Comprehensive Cancer CenterDuarteUSA
  2. 2.Department of Medical Oncology and Experimental TherapeuticsCity of Hope Comprehensive Cancer CenterDuarteUSA
  3. 3.UCSF School of MedicineSan FranciscoUSA

Personalised recommendations